At a glance
- Palmitoyl tripeptide-1 (Pal-GHK) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 7 publications mentioning it, including 0 randomized controlled trials and 0 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Permeation behaviour of cosmetic actives into the human stratum corneum.
- Mechanistic understanding and peptide ingredient screening for type III collagen via biological knowledge graph and molecular docking.
- EGCG-Biotin-Pal-GHK composition modulates TGF-β and BMP pathways in scalp microenvironment for treating stress-induced alopecia.
- Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.
- Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines.
- Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.